HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

RIBOLIFE-B

56.950

+2.6004.78%

Volume:281.60K

Turnover:16.00M

Market Cap:9.68B

PE:-27.12

High:57.650

Open:55.150

Low:54.950

Close:54.350

52wk High:95.800

52wk Low:43.600

Shares:170.00M

HK Float Shares:170.00M

Volume Ratio:1.53

T/O Rate:0.17%

Dividend:- -

Dividend Rate:- -

EPS(LYR):-2.100

ROE:-17.59%

ROA:-3.85%

PB:4.79

PE(LYR):-27.12

PS:17.85

Loading ...

Overview Company News Filings

RIBOLIFE-B Buys Back Shares for HK$4.22 Million

Suzhou Ribo Files HKEX Next-day Disclosure Return on Share Repurchase Cancellation

Ribo Discloses Positive Data from Vortosiran Phase 2a Trial - World's First Clinical Data on Sirna-mediated Fxi Inhibition Following Multiple Dosing in Patients with Coronary Artery Disease

THOMSON REUTERS

Suzhou Ribo Life Science Co - no Serious Adverse or Major Bleeding Events Observed in Vortosiran Phase 2a Trial

THOMSON REUTERS

Suzhou Ribo Reports Positive Phase 2a Results for Vortosiran

MT Newswires Live

RiboLife-B's Pioneering siRNA Drug Demonstrates Potent, Long-Lasting, and Safe Anticoagulation in New Data, Targeting a Multi-Billion Dollar Market

Positive Phase 2A Results for Vortosiran in Chronic Coronary Disease Announced

RIBOLIFE-B Spends HK$3.83 Million to Repurchase 79,000 H Shares, Treasury Stock Climbs to 0.49 Million

Bulletin Express

RIBOLIFE-B (06938) Executes HK$3.83 Million Share Buyback on July 17

RIBOLIFE-B (06938) Allocates HK$306,900 for Share Buyback on July 15

Suzhou Ribo Files HKEX Next-day Disclosure After Share Repurchase

Ribo Life Science executes HK$9.30 million on-market repurchase of 186,600 H shares

Bulletin Express

Suzhou Ribo Files HKEX Next-day Return Disclosing Share Buyback at HKD 49.85 Average Price

RIBOLIFE-B (06938) Repurchases 186,600 H-Shares on July 13 for HK$9.3012 Million

RIBOLIFE-B Shares Surge Nearly 5% in Afternoon Session, Securing "Buy" Rating from China Post Securities

Ribo Life Science executive Dr. Gan Liming lifts personal stake by 6,800 H shares, cumulative purchase reaches 20,000 shares

Bulletin Express

RIBOLIFE-B Executive Director Acquires Additional H Shares

Suzhou Ribo Director Gan Liming Lifts H-share Stake with 6,800-share Purchase

Suzhou Ribo Life Science Co - Co-ceo Purchases 6800 H Shares on Open Market

THOMSON REUTERS

Suzhou Ribo Life Science Co's Co-ceo Purchases 13,200 H Shares of Co

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg1.tigeractivity.com/stock/06938/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"06938","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"06938\",,,,,undefined,":{"symbol":"06938","market":"HK","secType":"STK","nameCN":"RIBOLIFE-B","latestPrice":56.95,"timestamp":1790755707008,"preClose":54.35,"halted":0,"volume":281600,"delay":0,"changeRate":0.04783808647654096,"floatShares":170000000,"shares":170000000,"eps":-2.100221,"marketStatus":"Closed National Day","change":2.6,"latestTime":"09-30 16:08:27","open":55.15,"high":57.65,"low":54.95,"amount":16003962,"amplitude":0.049678,"askPrice":57,"askSize":90000,"bidPrice":56.95,"bidSize":800,"shortable":3,"etf":0,"ttmEps":-1.149,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1790904600000},"marketStatusCode":7,"adr":0,"listingDate":1767888000000,"exchange":"SEHK","adjPreClose":54.35,"openAndCloseTimeList":[[1790731800000,1790740800000],[1790744400000,1790755200000]],"volumeRatio":1.5256257458436386,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"06938\",,,,,undefined,":{"symbol":"06938","floatShares":170000000,"roa":"-3.85%","roe":"-17.59%","lyrEps":-2.100221,"volumeRatio":1.5256257458436386,"shares":170000000,"dividePrice":0,"high":57.65,"amplitude":0.049678,"preClose":54.35,"low":54.95,"week52Low":43.6,"pbRate":"4.79","psRate":"17.85","week52High":95.8,"institutionHeld":0,"latestPrice":56.95,"committee":-0.982379,"eps":-2.100221,"divideRate":0,"volume":281600,"delay":0,"ttmEps":-1.149,"open":55.15,"prevYearClose":57.97,"prevWeekClose":52.3,"prevMonthClose":56.95,"prevQuarterClose":56.95,"fiveDayClose":55.5,"twentyDayClose":64,"sixtyDayClose":55.6},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/06938\",params:#limit:5,,,undefined,":[{"date":"2026-08-27","symbol":"06938","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787794200000,"name":null,"time":"","dateTimestamp":1787760000000,"actualEps":null},{"market":"HK","date":"2026-03-25","symbol":"06938","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1774368000000,"reportTimeType":"post","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"06938\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"06938\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0.25,"buy":0.75,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.75,"analysts":8,"updateTime":1784304000000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/06938\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"06938","date":"2026-09-30","current":-49.564839,"percent":0.078431,"low":-56.914635,"twenty":-44.047015,"median":-32.109735,"eighty":-26.898759,"high":-23.913403,"avg":-34.793976,"sd":8.499174,"marketCap":9713102124},"quantilePoints":[{"date":"2026-02-13","current":-47.784644,"twenty":-49.967526,"median":-49.148945,"eighty":-48.330365,"marketCap":11947371445},{"date":"2026-02-20","current":-49.493094,"twenty":-49.901155,"median":-49.02522,"eighty":-48.248265,"marketCap":12356703229},{"date":"2026-02-27","current":-46.28708,"twenty":-49.778496,"median":-48.557346,"eighty":-47.185619,"marketCap":11683011335},{"date":"2026-03-06","current":-41.043234,"twenty":-48.963884,"median":-47.035862,"eighty":-41.420692,"marketCap":10275933327},{"date":"2026-03-13","current":-37.939269,"twenty":-48.578839,"median":-43.677981,"eighty":-39.627323,"marketCap":9542547214},{"date":"2026-03-20","current":-38.832211,"twenty":-48.543939,"median":-40.85279,"eighty":-39.405242,"marketCap":9730157615},{"date":"2026-03-27","current":-30.985978,"twenty":-48.084787,"median":-40.112534,"eighty":-38.372934,"marketCap":9755740852},{"date":"2026-04-02","current":-34.881193,"twenty":-47.185618,"median":-39.757485,"eighty":-36.526858,"marketCap":11034902677},{"date":"2026-04-10","current":-37.770699,"twenty":-46.28708,"median":-39.613953,"eighty":-36.479378,"marketCap":12041176646},{"date":"2026-04-17","current":-35.241421,"twenty":-45.408639,"median":-38.832211,"eighty":-35.918978,"marketCap":11239568569},{"date":"2026-04-24","current":-33.421304,"twenty":-43.677981,"median":-38.300657,"eighty":-35.241421,"marketCap":10659681875},{"date":"2026-04-30","current":-32.557368,"twenty":-42.07346,"median":-37.836456,"eighty":-34.614071,"marketCap":10386794019},{"date":"2026-05-08","current":-32.498031,"twenty":-41.169053,"median":-37.354591,"eighty":-33.058756,"marketCap":10403849510},{"date":"2026-05-15","current":-32.120533,"twenty":-40.738524,"median":-36.586666,"eighty":-32.493391,"marketCap":10310044309},{"date":"2026-05-22","current":-30.090442,"twenty":-40.591323,"median":-35.918978,"eighty":-32.095834,"marketCap":9636352415},{"date":"2026-05-29","current":-30.88841,"twenty":-40.296947,"median":-35.448939,"eighty":-31.691849,"marketCap":9926295762},{"date":"2026-06-05","current":-28.193848,"twenty":-40.051892,"median":-35.061307,"eighty":-30.899503,"marketCap":9073521212},{"date":"2026-06-12","current":-27.046231,"twenty":-39.859077,"median":-34.61525,"eighty":-30.390832,"marketCap":8698300410},{"date":"2026-06-18","current":-26.187923,"twenty":-39.726813,"median":-33.720381,"eighty":-29.853022,"marketCap":8442468045},{"date":"2026-06-26","current":-23.913403,"twenty":-39.627323,"median":-32.945231,"eighty":-29.564677,"marketCap":7671559851},{"date":"2026-07-03","current":-27.120201,"twenty":-39.476172,"median":-32.527699,"eighty":-28.324896,"marketCap":8706828155},{"date":"2026-07-10","current":-25.658884,"twenty":-39.120404,"median":-32.474833,"eighty":-27.529192,"marketCap":8227568858},{"date":"2026-07-17","current":-25.917703,"twenty":-38.802803,"median":-32.09845,"eighty":-26.657872,"marketCap":8340135099},{"date":"2026-07-24","current":-28.402389,"twenty":-38.680546,"median":-32.07594,"eighty":-26.891702,"marketCap":9141743176},{"date":"2026-07-31","current":-24.94248,"twenty":-38.662044,"median":-31.566896,"eighty":-26.553964,"marketCap":8043369555},{"date":"2026-08-07","current":-27.580979,"twenty":-37.939269,"median":-30.913769,"eighty":-26.515913,"marketCap":8911494047},{"date":"2026-08-14","current":-27.888785,"twenty":-37.902214,"median":-30.842167,"eighty":-26.553964,"marketCap":9022354739},{"date":"2026-08-21","current":-28.090305,"twenty":-37.770699,"median":-30.35874,"eighty":-26.553964,"marketCap":9107632194},{"date":"2026-08-28","current":-53.27383,"twenty":-37.770699,"median":-30.842167,"eighty":-26.562391,"marketCap":10540293438},{"date":"2026-09-04","current":-56.914635,"twenty":-38.685171,"median":-30.913769,"eighty":-26.600296,"marketCap":11265151805},{"date":"2026-09-11","current":-46.597638,"twenty":-39.680804,"median":-31.566896,"eighty":-26.683608,"marketCap":9235548376},{"date":"2026-09-18","current":-45.763368,"twenty":-40.573567,"median":-31.94791,"eighty":-26.713454,"marketCap":9082048957},{"date":"2026-09-25","current":-45.032759,"twenty":-43.119513,"median":-32.097963,"eighty":-26.888174,"marketCap":8920021793},{"date":"2026-09-30","current":-48.945314,"twenty":-44.047015,"median":-32.109735,"eighty":-26.898759,"marketCap":9713102124}],"updateTime":1790827142000},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"06938\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1162346052","title":"RIBOLIFE-B Buys Back Shares for HK$4.22 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=1162346052","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1162346052?lang=en_us&edition=fundamental","pubTime":"2026-07-24 20:44","pubTimestamp":1784897051,"startTime":"0","endTime":"0","summary":"RIBOLIFE-B (06938) announced a share buyback on July 24, 2026.The company spent approximately HK$4.2237 million to repurchase 78,400 shares.The repurchase price ranged from HK$52.6 to HK$54.4 per share.","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653808262","title":"Suzhou Ribo Files HKEX Next-day Disclosure Return on Share Repurchase Cancellation","url":"https://stock-news.laohu8.com/highlight/detail?id=2653808262","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653808262?lang=en_us&edition=fundamental","pubTime":"2026-07-24 20:37","pubTimestamp":1784896639,"startTime":"0","endTime":"0","summary":"Suzhou Ribo files HKEX next-day disclosure return on share repurchase cancellationSuzhou Ribo repurchased 78,400 H shares on July 24 for treasury, no shares repurchased for cancellation.Buyback price ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260724:nNDL2ZBZxp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653750982","title":"Ribo Discloses Positive Data from Vortosiran Phase 2a Trial - World's First Clinical Data on Sirna-mediated Fxi Inhibition Following Multiple Dosing in Patients with Coronary Artery Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2653750982","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653750982?lang=en_us&edition=fundamental","pubTime":"2026-07-22 20:23","pubTimestamp":1784723004,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260722:nTUA5PZQHL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["06938","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653075098","title":"Suzhou Ribo Life Science Co - no Serious Adverse or Major Bleeding Events Observed in Vortosiran Phase 2a Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2653075098","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653075098?lang=en_us&edition=fundamental","pubTime":"2026-07-22 20:23","pubTimestamp":1784723004,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260722:nTUA5PZQHL:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["06938","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653752817","title":"Suzhou Ribo Reports Positive Phase 2a Results for Vortosiran","url":"https://stock-news.laohu8.com/highlight/detail?id=2653752817","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653752817?lang=en_us&edition=fundamental","pubTime":"2026-07-22 19:09","pubTimestamp":1784718575,"startTime":"0","endTime":"0","summary":"Suzhou Ribo Life Science  reported positive Phase 2a results for its investigational therapy vortosiran  in patients with chronic coronary artery disease.The study showed the small interfering RNA therapy was generally well tolerated and achieved dose-dependent, long-lasting suppression of coagulation factor XI activity in patients receiving aspirin therapy, with no treatment-related serious adverse events or major bleeding reported, according to a Hong Kong bourse filing on Wednesday.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1161","06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146461811","title":"RiboLife-B's Pioneering siRNA Drug Demonstrates Potent, Long-Lasting, and Safe Anticoagulation in New Data, Targeting a Multi-Billion Dollar Market","url":"https://stock-news.laohu8.com/highlight/detail?id=1146461811","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1146461811?lang=en_us&edition=fundamental","pubTime":"2026-07-22 19:03","pubTimestamp":1784718212,"startTime":"0","endTime":"0","summary":"RiboLife-B (06938) has unveiled new Phase IIa data for its core candidate, Vortosiran (RBD4059), at the CPIC conference, reinforcing the drug's profile as a potent, durable, and safe therapy. The...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172610777","title":"Positive Phase 2A Results for Vortosiran in Chronic Coronary Disease Announced","url":"https://stock-news.laohu8.com/highlight/detail?id=1172610777","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1172610777?lang=en_us&edition=fundamental","pubTime":"2026-07-22 16:38","pubTimestamp":1784709529,"startTime":"0","endTime":"0","summary":"RIBOLIFE-B (ASX: 06938) has announced the presentation of positive results from a European Phase 2a study evaluating vortosiran (RBD4059) in patients with chronic coronary artery disease (CAD). The...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1152367346","title":"RIBOLIFE-B Spends HK$3.83 Million to Repurchase 79,000 H Shares, Treasury Stock Climbs to 0.49 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=1152367346","media":"Bulletin Express","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1152367346?lang=en_us&edition=fundamental","pubTime":"2026-07-17 19:21","pubTimestamp":1784287280,"startTime":"0","endTime":"0","summary":"Suzhou Ribo Life Science Co., Ltd. (RIBOLIFE-B; HKEX: 06938) disclosed a share buyback executed on 17 July 2026. The company repurchased 79,000 H shares on the Hong Kong Stock Exchange at prices...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113024488","title":"RIBOLIFE-B (06938) Executes HK$3.83 Million Share Buyback on July 17","url":"https://stock-news.laohu8.com/highlight/detail?id=1113024488","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1113024488?lang=en_us&edition=fundamental","pubTime":"2026-07-17 19:11","pubTimestamp":1784286714,"startTime":"0","endTime":"0","summary":"RIBOLIFE-B (ASX: 06938) has disclosed the execution of a share repurchase on July 17, 2026. The company repurchased 79,000 of its own shares, with the total expenditure for the transaction amounting to approximately HK$3.83 million.","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1155049285","title":"RIBOLIFE-B (06938) Allocates HK$306,900 for Share Buyback on July 15","url":"https://stock-news.laohu8.com/highlight/detail?id=1155049285","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1155049285?lang=en_us&edition=fundamental","pubTime":"2026-07-15 19:14","pubTimestamp":1784114056,"startTime":"0","endTime":"0","summary":"On July 15, 2026, RIBOLIFE-B (ASX: 06938) executed a share repurchase, utilizing HK$306,900 to acquire 6,200 of its own shares.","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651457540","title":"Suzhou Ribo Files HKEX Next-day Disclosure After Share Repurchase","url":"https://stock-news.laohu8.com/highlight/detail?id=2651457540","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651457540?lang=en_us&edition=fundamental","pubTime":"2026-07-15 19:11","pubTimestamp":1784113909,"startTime":"0","endTime":"0","summary":"Suzhou Ribo files HKEX next-day disclosure after share repurchaseSuzhou Ribo repurchased 6,200 H shares on July 15, held as treasury shares; no shares were repurchased for cancellation.Buyback execute","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260715:nNDL46kJkJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181401404","title":"Ribo Life Science executes HK$9.30 million on-market repurchase of 186,600 H shares","url":"https://stock-news.laohu8.com/highlight/detail?id=1181401404","media":"Bulletin Express","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1181401404?lang=en_us&edition=fundamental","pubTime":"2026-07-13 22:06","pubTimestamp":1783951583,"startTime":"0","endTime":"0","summary":"Ribo Life Science (Suzhou Ribo Life Science Co., Ltd.) disclosed that it bought back 186,600 H shares on 13 July 2026 under its existing shareholder-approved mandate. The transaction totalled HK$9.30...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651217112","title":"Suzhou Ribo Files HKEX Next-day Return Disclosing Share Buyback at HKD 49.85 Average Price","url":"https://stock-news.laohu8.com/highlight/detail?id=2651217112","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651217112?lang=en_us&edition=fundamental","pubTime":"2026-07-13 21:54","pubTimestamp":1783950892,"startTime":"0","endTime":"0","summary":"Suzhou Ribo files HKEX next-day return disclosing share buyback at HKD 49.85 average priceSuzhou Ribo Life Science filed a next-day disclosure return reporting a repurchase of 186,600 H shares on July","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260713:nNDL6jGHbb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159820551","title":"RIBOLIFE-B (06938) Repurchases 186,600 H-Shares on July 13 for HK$9.3012 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=1159820551","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1159820551?lang=en_us&edition=fundamental","pubTime":"2026-07-13 21:52","pubTimestamp":1783950737,"startTime":"0","endTime":"0","summary":"On July 13, RIBOLIFE-B (ASX: 06938) disclosed its share repurchase activity for the day. The company acquired a total of 186,600 H-shares in the open market. The total expenditure for this transaction amounted to HK$9.3012 million. All the repurchased H-shares are being held as treasury stock.","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128833810","title":"RIBOLIFE-B Shares Surge Nearly 5% in Afternoon Session, Securing \"Buy\" Rating from China Post Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=1128833810","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1128833810?lang=en_us&edition=fundamental","pubTime":"2026-07-13 14:50","pubTimestamp":1783925442,"startTime":"0","endTime":"0","summary":"Shares of RIBOLIFE-B (06938) rose more than 6% during the trading session. At the time of writing, the stock is up 4.69%, trading at HK$50.50 with a turnover of HK$15.096 million. RIBOLIFE-B issued...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","06938","161027"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1138010880","title":"Ribo Life Science executive Dr. Gan Liming lifts personal stake by 6,800 H shares, cumulative purchase reaches 20,000 shares","url":"https://stock-news.laohu8.com/highlight/detail?id=1138010880","media":"Bulletin Express","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1138010880?lang=en_us&edition=fundamental","pubTime":"2026-07-10 18:23","pubTimestamp":1783678987,"startTime":"0","endTime":"0","summary":"Suzhou Ribo Life Science Co., Ltd. (Ribo Life Science) disclosed that executive director, co-chief executive officer and global R&D president Dr. Gan Liming bought 6,800 H shares of the company on...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1102637458","title":"RIBOLIFE-B Executive Director Acquires Additional H Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=1102637458","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1102637458?lang=en_us&edition=fundamental","pubTime":"2026-07-10 18:22","pubTimestamp":1783678939,"startTime":"0","endTime":"0","summary":"RIBOLIFE-B (ASX: 06938) has announced that the company's board was recently informed by Dr. Gan Liming, an executive director, co-CEO, and global head of R&D, that he has used personal funds to...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650181928","title":"Suzhou Ribo Director Gan Liming Lifts H-share Stake with 6,800-share Purchase","url":"https://stock-news.laohu8.com/highlight/detail?id=2650181928","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650181928?lang=en_us&edition=fundamental","pubTime":"2026-07-10 18:18","pubTimestamp":1783678692,"startTime":"0","endTime":"0","summary":"Suzhou Ribo director Gan Liming lifts H-share stake with 6,800-share purchaseExecutive director Gan Liming bought 6,800 H shares on-market, lifting his cumulative purchases to 20,000 H shares as of Ju","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260710:nNDL8vqqXr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Suzhou Ribo Director Gan Liming Lifts H-share Stake with 6,800-share Purchase","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650819401","title":"Suzhou Ribo Life Science Co - Co-ceo Purchases 6800 H Shares on Open Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2650819401","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650819401?lang=en_us&edition=fundamental","pubTime":"2026-07-10 18:18","pubTimestamp":1783678682,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260710:nFWN43C0K0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["06938","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649983876","title":"Suzhou Ribo Life Science Co's Co-ceo Purchases 13,200 H Shares of Co","url":"https://stock-news.laohu8.com/highlight/detail?id=2649983876","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649983876?lang=en_us&edition=fundamental","pubTime":"2026-07-07 16:47","pubTimestamp":1783414046,"startTime":"0","endTime":"0","summary":"July 3 (Reuters) - Suzhou Ribo Life Science Co Ltd <6938.HK>::*CO-CEO PURCHASES 13,200 H SHARES OF SUZHOU RIBO LIFE SCIENCE*Further company coverage: 6938.HK* ((Reuters.Briefs@thomsonreuters.com;))((R","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260707:nRSD19bMPT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938","BK1161"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":2,"totalSize":86,"code":"91000000","status":"200"}]}}